Hiroaki Akamatsu

23PUBLICATIONS
170CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Jul 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

|Mar 30, 2026
Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non-Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study.

Toshiaki Takakura, Ryota Shibaki, Atsushi Washioka

|Feb 02, 2026
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab.

Atsuto Mouri, Hiroshi Kagamu, Koji Tamada

|Jan 29, 2026
Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

Jong-Seok Lee, Shunichi Sugawara, Jin-Hyoung Kang

|Apr 16, 2025
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi

Pageof 4

Frequent Collaborators

4 joint publications

Makoto Nishio

4 joint publications

Satoru Miura

3 joint publications

Yasushi Goto

3 joint publications

Tetsuya Mitsudomi